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Mutations in more than a hundred genes have been reported to cause X-linked recessive intellectual disability (ID) mainly in males. In
contrast, the number of identified X-linked genes in which de novomutations specifically cause ID in females is limited. Here, we report
17 females with de novo loss-of-function mutations in USP9X, encoding a highly conserved deubiquitinating enzyme. The females in
our study have a specific phenotype that includes ID/developmental delay (DD), characteristic facial features, short stature, and distinct
congenitalmalformations comprising choanal atresia, anal abnormalities, post-axial polydactyly, heart defects, hypomastia, cleft palate/
bifid uvula, progressive scoliosis, and structural brain abnormalities. Four females from our cohort were identified by targeted genetic
testing because their phenotype was suggestive for USP9X mutations. In several females, pigment changes along Blaschko lines and
body asymmetry were observed, which is probably related to differential (escape from) X-inactivation between tissues. Expression
studies on both mRNA and protein level in affected-female-derived fibroblasts showed significant reduction of USP9X level, confirming
the loss-of-function effect of the identifiedmutations. Given that some features of affected females are also reported in known ciliopathy
syndromes, we examined the role of USP9X in the primary cilium and found that endogenous USP9X localizes along the length of the
ciliary axoneme, indicating that its loss of function could indeed disrupt cilium-regulated processes. Absence of dysregulated ciliary
parameters in affected female-derived fibroblasts, however, points toward spatiotemporal specificity of ciliary USP9X (dys-)function.X-linked intellectual disability (ID) with presumed reces-
sive inheritance pattern is shown to be caused by muta-
tions in more than a hundred genes.1,2 Most families
display a clear X-linked segregation pattern, in which
males are affected and females are unaffected or mildly
affected carriers.3–5 In contrast, the number of identified
X-linked genes in which de novo mutations cause ID spe-
cifically in females is limited.
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Figure 1. Identified De Novo USP9X Loss-of-Function Mutations
(A) Detailed view of the USP9X (GenBank: NM_001039590.2) region and the reported deletions.
(B) Overview of USP9X includingUBL and catalytic domain and the location of reportedmutations according to their relative position at
the protein level. The reported amino acid substitution is located within the catalytic domain.
(C) RNA was extracted from both control and affected female (c.30282A>G [p.(?)]) fibroblasts cultured under normal conditions
or in the presence of cycloheximide (CHX) to inhibit NMD. After cDNA synthesis and PCR, agarose gel analysis showed two
different product sizes generated from the c.30282A>G transcript but only one from the control fibroblast transcript. Excision
and sequencing of the additional band revealed that the aberrant USP9X transcript lacked exon 21. The level of the aberrant transcript
was increased 4-fold when fibroblasts were treated with cycloheximide, confirming that the aberrant transcript was indeed subjected
to NMD.
(legend continued on next page)
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Table 1. Clinical Features of Females with De Novo USP9X Loss-of-
Function Mutations
Percentage Number
Development
Intellectual disability or developmental delay 100% 17/17
Growth
Short stature 53% 9/17
Congenital Abnormalities
Eye abnormality 59% 10/17
Choanal atresia 35% 6/17
Cleft palate/bifid uvula 29% 5/17
Dental abnormality 71% 12/17
Asymmetric hypomastia 29% 5/17
Heart defect 44% 7/16
Urogenital abnormality 29% 5/17
Sacral dimple 29% 5/17
Scoliosis 65% 11/17
Hip dysplasia 47% 8/17
Post-axial polydactyly 53% 9/17
Abdominal wall abnormality 12% 2/17
Anal atresia 53% 9/17
Neurology
Seizures 24% 4/17
Hypotonia 47% 8/17
Brain Abnormalities
Dandy walker malformation (variant) 38% 5/13
Hypoplastic corpus callosum 62% 8/13
(Asymmetric) cerebellar hypoplasia 55% 6/11
(Asymmetric) enlarged ventricles 73% 8/11
Thin brain stem 30% 3/10
Abnormal gyration pattern frontal lobe 50% 5/10
Other
Hearing loss 65% 11/17
(Blaschko) pigment abnormality 65% 11/17
Hypertrichosis 29% 5/17
Leg length discrepancy 41% 7/17
Malignancy 12% 2/17
Recurrent respiratory tract infections 53% 9/17
Thyroid hormone abnormality 35% 6/17similar pattern of facial characteristics, congenital malfor-
mations, and brain abnormalities in these females. Four
additional affected females were identified because their
phenotype was suggestive for USP9X mutations. Subse-
quently, de novo protein-truncating mutations and intra-
genic USP9X deletions were duly demonstrated by Sanger
sequencing, WES, or CytoScan HD array (Figures 1A and
1B; Table S1), illustrating the clinical recognizability of
this new syndrome. All females (age ranging 2 years,
7 months to 23 years) with de novo mutations shared a
distinct phenotype. They showed mild to moderate ID
with motor and language delay, short stature, hearing
loss, and distinct congenital malformations, notably choa-
nal atresia, asymmetric hypomastia, cleft palate/bifid
uvula, heart defects, progressive scoliosis, post-axial poly-
dactyly, and anal abnormalities (Tables 1 and S2; case
studies in Supplemental Note). Shared facial characteristics
included prominent forehead, low nasal bridge, prominent
nose with flared alae nasi, thin upper lip, smooth and long
philtrum, and ears that were low set, posteriorly rotated,
and dysplastic (Figure 2A). In addition to the USP9X
variant, female 5 also harbored a de novo variant in
PTPN11 (MIM: 176876), which has previously been re-
ported to cause Noonan syndrome (MIM: 163950).12
Though all features that were observed in this female could
potentially be explained by the USP9X variant itself
(Table S2), a contribution of aberrant PTPN11 to pheno-
typic features such as intellectual disability, short stature,
and heart defect in this female is likely. Neuroimaging
reports were available for 13 out of 17 females (Table S2).
Detailed evaluation of brain images of five of these females
(females 1, 2, 3, 7, and 16) showed asymmetric hypoplasia
of the cerebellar vermis and hemisphere with a retrocere-
bellar cyst, short and thin corpus callosum, thin brainstem,
and mildly abnormal frontal gyration pattern (Figure 3).
Notably, we observed thyroid hormone abnormalities in
six of the females, requiring medical treatment in three
of them.
The X-linkedUSP9X encodes a structurally and function-
ally highly conserved deubiquitinating enzyme, contain-
ing a UBL (ubiquitin-like) and a catalytic ubiquitin specific
protease (USP) domain.13–15 It is known to play an impor-
tant role in neural development of both humans and mice
and is required for fetal development.16–18 USP9X is highly
expressed during embryogenesis and expression declines
as cell fates become restricted.18 The USP9X ortholog in
Drosophila, fat facets (faf), has been shown to be important
in cell polarity and cell fate of the developing eye in
Drosophila.19 A range of signaling proteins involved in
different neurodevelopmental pathways including Notch,(D) USP9X expression is depleted in female cell lines harboring loss-of-function alleles. Relative qPCR analysis of USP9XmRNA and rela-
tive quantification of immunoblot analysis of USP9X protein derived from female and male control cell lines and from affected female
cell lines. n ¼ the number of individual cell lines analyzed. Each cell line analyzed in quadruplicate. Error bars represent SDs. Asterisk (*)
indicates significantly different to female controls, p < 0.05 by Student’s t test.
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Figure 2. Clinical Characteristics of Females with De Novo USP9X Loss-of-Function Mutations
(A) Frontal and lateral photographs of females with de novo mutations in USP9X. Shared facial characteristics include facial asymmetry,
prominent forehead, bitemporal narrowing, short palpebral fissures, low nasal bridge, prominent nose with flared alae nasi from adoles-
cence age, thin upper lip, smooth and long philtrum, hanging full cheeks in early childhood, and low-set, posteriorly rotated, and
dysplastic ears with attached lobule.
(B) Photographs of the hands of seven affected females. Shared characteristics include ulnar deviation of 5th digit, tapered fingers, short
4th and 5th metacarpals, and post-axial polydactyly (simian crease present but not shown).
(C) Photographs of the feet of five affected females. Shared characteristics include hallux valgus and sandal gap (pes cavus present but not
shown).
(D) Observed Blaschko lines of female 3, indicative for 11 of the affected females, suggestive of different X-inactivation pattern between
tissues (functional mosaicism).Wnt, TGF-b, and mTOR have been shown to interact with
USP9X.14,20–27 USP9X also has been described to act as
both an oncogene and tumor-suppressor gene and is
frequently found to be dysregulated in human can-
cer.14,28,29 Two of the affected females developed malig-
nancy at a young age (22 and 8 years). Both acute
lymphoblastic leukemia and osteosarcoma were treated
successfully and have not reoccurred. To determine the
risk and nature of particular malignancies in this new syn-
drome, further studies are required.
We observed pigment abnormalities along Blaschko
lines and facial asymmetry, asymmetric abnormalities of
the brain and breast, and asymmetric length of the legs
(Figures 2A, 2D, and 3), all suggestive of a pattern of
post-zygotic mosaicism or differential X-inactivation
(XCI) between tissues (functional mosaicism).30 USP9X is
one of the genes shown to escape XCI.31,32 However, it is
known that most of the genes that escape from XCI are
not fully expressed from the inactivated X chromosome
and instead show a partial escape.33–35 Moreover, there is
accumulating evidence for tissue-specific and develop-
mental-stage-dependent differences in XCI and variability
of escape of USP9X.34,36–39 In the partial escaping genes,
non-random XCI or skewing, as observed often in female
carriers of an X-linked mutation, will only partially restore
a normal phenotype.35 Consistent with this hypothesis,
XCI was found to be skewed >90% in fibroblasts in three376 The American Journal of Human Genetics 98, 373–381, Februaryof the five of the tested females, but skewing was not
related to disease severity (Table S3). We note that a similar
skewing pattern of XCI was observed recently in females
with de novo mutations in DDX3X (MIM: 300160),
another X-chromosomal gene that has been suggested
to escape XCI and in which de novo mutations cause ID
specifically in females.40
In one of the affected females, a predicted splice site
mutation was identified. To evaluate whether this muta-
tion indeed results in an aberrant transcript, we synthe-
sized cDNA from RNA extracted from primary skin fibro-
blasts of both the affected female and a control. We
amplified a fragment of 576 base pairs (bp) covering
exon 20 to exon 22 by PCR. Electrophoretic separation
showed two products of 576 and 455 bp in the sample
from the affected female, and a single 576-bp product
in the control. Sequencing of the smaller product re-
vealed that this cDNA transcript from the affected female
indeed lacked exon 21, confirming the truncating effect
of the splice site mutation. Importantly, the level of the
transcript was increased 4-fold when fibroblasts were
treated with cycloheximide, strongly suggesting that the
aberrant transcript was subjected to nonsense-mediated
mRNA decay and as such leads to loss of function of
this USP9X allele (Figure 1C). To study the effect of the
heterozygous loss-of-function USP9X alleles on their
mRNA expression and protein levels, we performed4, 2016
Figure 3. Representative MRI Images
from Females 1, 2, 3, 7, and 16 with De
Novo USP9X Loss-of-Function Mutations
(A–D) Female 1 (2 years): MRI T2 axial
(A, B) and sagittal (C) and T1 axial (D) sec-
tions show brachycephaly, mild enlarge-
ment of the lateral and 3rd ventricles;
mild hypoplasia of cerebellar vermis and
left cerebellar hemisphere; enlarged IV
ventricle and cisterna magna with small
retrocerebellar cyst; thin brain stem and
mesencephalon; relatively small frontal
lobes with somewhat simplified gyration;
and short hypoplastic corpus callosum
(both rostrum and splenium).
(E–H) Female 2 (1.5 years): MRI T2 axial
(E, F) and T1 sagittal (G) and coronal (H)
sections show enlargement of the lateral
ventricles, mild hypoplasia of cerebellar
vermis and left cerebellar hemisphere;
enlarged cistern magna; thin corpus cal-
losum, pons, mesencephalon, and brain
stem; and broader and underdeveloped
frontal gyri.
(I–L) Female 3 (11 years): MRI T2 axial (I, J)
and T1 sagittal (K) and axial (L) sections
show asymmetric enlargement of the
lateral ventricles; simplified convolutions
of the frontal lobe gyri; hypoplasia of cere-
bellar vermis and left hemisphere; large
cisterna magna and retrocerebellar cyst;
and thin corpus callosum with hypoplasia
of the rostrum.
(M–P) Female 7: MRI T2 axial (M), T1 axial
(N), T1 sagittal (O), and coronal FLAIR (P)
sections show macrocephaly; enlargement
of the lateral and 3rd ventricles with an
interhemispheric cyst; dysplastic cerebellar
hemispheres; dysplasia of the cerebellar
vermis which is uplifted, with a high posi-
tion of the tentorium and a large posterior
fossa, typical of Dandy-Walker malforma-
tion; and thin and hypoplastic corpus
callosum.
(Q–T) Female 16 (2 years): MRI T2 axial
(Q, R, S) and T1 coronal (T) sections show
enlarged lateral ventricles; irregular gyri of
the cerebral cortex with irregular depth of
the sulci in frontal and perisylvian areas;
small heterotopic nodule of gray matter (arrow) and thin and hypoplastic corpus callosum (both rostrum and splenium); hypoplasia
of the anterior cerebellar vermis and left cerebellar hemisphere; enlarged cisterna magna and arachnoidal cyst surrounding the cere-
bellum, especially at the left side; and mild hypoplasia of pons and brain stem. This female was identified with Sanger sequencing based
on these brain abnormalities in combination with ID, dysmorphic features, and congenital abnormalities.both qRT-PCR and immunoblot analysis of fibroblasts
(n ¼ 4) and lymphoblastoid cell lines (LCLs; n ¼ 1)
derived from affected females and both female and
male controls (Figures 1D and S1). We found that expres-
sion of USP9X in affected females was reduced compared
to control females in both fibroblasts and LCLs at both
mRNA expression and protein levels. Although some
cellular variability was evident, on average this decrease
was significant (p < 0.05 by Student’s t test) (Figures 1D
and S1). There was no correlation between skewing of
XCI and expression of mRNA and protein level. Whether
the cells in affected tissue have benefit from the skewed
XCI remains uncertain. The escape from XCI was sup-The Americported by the fact that the average expression of USP9X
mRNA in both control male fibroblasts and control
male LCLs was ~50% of that in female controls. After
quantification of protein levels in male control LCLs,
similar levels were observed. The USP9X protein level in
male control fibroblasts was increased to ~80% of that
in female controls, but was still significantly less than
the protein level in female controls. Intriguingly, these
data thus reveal that affected females displayed reduced
levels of USP9X compared to female controls but compa-
rable levels to that in healthy control males. It will be
important to expose whether these trends extend to
other tissues, where the level of escape from XCI mightan Journal of Human Genetics 98, 373–381, February 4, 2016 377
Figure 4. USP9X Localizes to the Primary Cilium
To induce ciliogenesis, control and affected female fibroblasts, matched for gender and age, were starved for 48 hr prior to immunoflu-
orescence labeling. Endogenous USP9X is detected along the length of the axoneme of primary cilia, using an antibody against its
N terminus (N-Term, shown in green) as compared to the ciliary markers RPGRIP1L (pink, denoting the ciliary transition zone at the
base of the cilium) and acetylated alpha-tubulin (red, marking the ciliary axoneme). DAPI (blue) stains the nuclei; scale bars represent
10 mm. Ciliated fibroblasts derived from affected females are shown here, USP9X localization in control fibroblasts is shown in Figure S2.not be comparable. Furthermore, characterization of
different expression patterns between sexes (described
for USP9X in brain thus far41) and/or that of protein
levels of USP9X substrates will be important to ascertain
as well.
In contrast to the severely disruptive de novo mutations
in females, three milder mutations in USP9X have been re-
ported in males without multiple congenital malforma-
tions. The mutations were transmitted by phenotypically
normal females and resulted in ID, hypotonia, and behav-
ioral problems in the males.42 An additional two missense
mutations were identified after resequencing of USP9X in
a cohort of 284 males with epilepsy.43 For two de novo
mutations reported in large autism cohorts, no specific
gender information was described.44 The phenotype of
the males differs notably from the observed phenotype
in the affected females described here. They had ID and
short stature, but lacked the multiple congenital malfor-
mations observed in affected females. Besides four
missense mutations, one frameshift mutation has been
reported in the males. This single frameshift mutation
occurred within the last 50 nucleotides upstream of
the last 30-exon-exon junction, presumably escaping
nonsense-mediated mRNA decay (NMD), and therefore
results in a truncated protein lacking the last exon.45,46
Because no truncating variants have been described in
healthy controls in the ExAC database and no mutations
causing loss of function of USP9X have been reported in
males, we suspect that loss-of-function mutations could
be lethal in males. This hypothesis is further supported
by the fact that the absence of Usp9X in male mice is
embryonically lethal.47 In contrast, all but one of the
affected females we report here have protein-truncating
mutations and deletions. In one female, we identified a
de novo missense mutation, located in the catalytic378 The American Journal of Human Genetics 98, 373–381, Februarydomain of the protein. Given the fact that this female
was phenotypically comparable with the other females,
it is likely that this specific missense mutation leads to
loss of function of the protein. We hypothesize that in
addition to complete loss-of-function mutations, such as
protein-truncating mutations and deletions, a small sub-
set of specific missense mutations will also lead to disease
in females.
Affected females presented with symptoms that overlap
with CHARGE syndrome (MIM: 214800) (CHD7 [MIM:
608892] tested in four of the females) and with the clin-
ical spectrum of some known ciliopathy syndromes,
such as Bardet-Biedl, Meckel-Gruber, and Joubert syn-
dromes.48 Therefore, we investigated whether heterozy-
gous protein-truncating mutations result in the disruption
of ciliary structure, formation, or trafficking in fibroblasts
of four of the affected females we had available (females
1, 3, 14, and 15). First, we determined subcellular locali-
zation of endogenous USP9X in both controls and
affected-female-derived fibroblasts under serum starvation
to induce ciliogenesis, as well as in serum-rich condi-
tions.49,50 USP9X showed diffuse cytoplasmic staining
with areas enriched with puncta consistent with its
described association with protein and vesicle traf-
ficking.51 Importantly, upon the induction of ciliogenesis
in the fibroblasts, USP9X was indeed found to localize to
the cilium. This ciliary localization was observed along
the length of the ciliary axoneme of most fibroblasts,
and comparable in cells from affected females and from
age- and gender-matched controls (Figure 4). This localiza-
tion was significantly decreased with siRNA knockdown of
USP9X indicating specificity of the signal (Figure S2). We
were unable to observe any significant differences in cilio-
genesis, ciliary length, or ciliary trafficking between fibro-
blasts from affected females when compared to controls4, 2016
(Figure S3), and siRNA knockdown of USP9X did not
impair ciliogenesis in fibroblasts. This suggests that
USP9X dosage is not critical to the generation of primary
cilia in these fibroblasts, despite localization of USP9X in
their cilia. It is therefore more likely that USP9X-regulated
signal transduction pathways mediated by the primary
cilium are more subtly disturbed, and/or that this distur-
bance is spatiotemporally restricted to the tissues affected
in this specific phenotype, possibly due to tissue-specific
and developmental-stage-dependent differences in XCI
and variability of escape of USP9X. Future studies utilizing
dedicated cell-based or animal models will be necessary to
evaluate these mechanisms.
In conclusion, this study defines a recognizable X-linked
ID/DD syndrome with associated multiple congenital mal-
formations and brain abnormalities specific to females,
caused by de novo loss-of-function mutations in USP9X, a
geneknown toescapeX-inactivation. Thephenotypic char-
acteristics overlap with ciliopathy conditions and USP9X
localization along the length of the ciliary axoneme of
fibroblasts indicates a role in de-ubiquitination of ciliary
proteins, which could contribute to the disease pathogen-
esis of this specific syndrome.Accession Numbers
The accession numbers of the CNV data reported in this paper are
DECIPHER: 322370, 322371, 322372, and 322375.Supplemental Data
Supplemental Data include Supplemental Acknowledgments, case
reports in a Supplemental Note, three figures, and three tables and
can be found with this article online at http://dx.doi.org/10.1016/
j.ajhg.2015.12.015.Acknowledgments
We thank all the families for their contributions. We thank
J. Hehir-Kwa, N. de Leeuw, and N. Nadif-Kasri for providing
data and useful discussions. This work was supported by grants
from the Netherlands Organization for Health Research and
Development, ZonMw (grant 907-00-365 to T.K.) and the
Netherlands Organization for Scientific Research (NWO Vici-
865.12.005 to R.R.). A.N., A.H.-S., H.M., B.-M.M.A., and V.Z.
were supported through the regional agreement on medical
training and clinical research (ALF) between Stockholm County
Council and Karolinska Institutet, by grants from Frimurare
Barnhuset i Stockholm, The Cancer Research Foundations of
Radiumhemmet, The Swedish Childhood Cancer Foundation,
and the Karolinska Institutet research funds. J.G. was supported
by Australian National Health and Medical Research Council
(NHMRC) Program Grant (628952) and Research Fellowship
(1041920). B.R. is a fellow of the Branco Weiss Foundation, an
EMBO Young Investigator, and a recipient of the A*STAR Inves-
tigatorship. This work was partly funded by a Strategic Posi-
tioning Fund on Genetic Orphan Diseases and an Industry
Alignment Fund seeding grant from the Biomedical Research
Council, A*STAR, Singapore. Acknowledgments of the DDD
Study are included in the Supplemental Data.The AmericReceived: November 11, 2015
Accepted: December 15, 2015
Published: January 28, 2016Web Resources
The URLs for data presented herein are as follows:
DECIPHER, http://decipher.sanger.ac.uk/
Ensembl Genome Browser, http://www.ensembl.org/index.html
ExAC Browser, http://exac.broadinstitute.org/
OMIM, http://www.omim.org/
RefSeq, http://www.ncbi.nlm.nih.gov/RefSeq
UCSC Genome Browser, http://genome.ucsc.eduReferences
1. Lubs, H.A., Stevenson, R.E., and Schwartz, C.E. (2012). Fragile
X and X-linked intellectual disability: four decades of discov-
ery. Am. J. Hum. Genet. 90, 579–590.
2. Piton, A., Redin, C., and Mandel, J.L. (2013). XLID-causing
mutations and associated genes challenged in light of data
from large-scale human exome sequencing. Am. J. Hum.
Genet. 93, 368–383.
3. Tarpey, P.S., Smith, R., Pleasance, E., Whibley, A., Edkins, S.,
Hardy, C., O’Meara, S., Latimer, C., Dicks, E., Menzies, A.,
et al. (2009). A systematic, large-scale resequencing screen of
X-chromosome coding exons in mental retardation. Nat.
Genet. 41, 535–543.
4. Hu, H., Haas, S.A., Chelly, J., Van Esch, H., Raynaud, M., de
Brouwer, A.P., Weinert, S., Froyen, G., Frints, S.G., Laumon-
nier, F., et al. (2016). X-exome sequencing of 405 unresolved
families identifies seven novel intellectual disability genes.
Mol. Psychiatry 21, 133–148.
5. Whibley, A.C., Plagnol, V., Tarpey, P.S., Abidi, F., Fullston, T.,
Choma, M.K., Boucher, C.A., Shepherd, L., Willatt, L., Parkin,
G., et al. (2010). Fine-scale survey of X chromosome copy
number variants and indels underlying intellectual disability.
Am. J. Hum. Genet. 87, 173–188.
6. de Ligt, J., Willemsen, M.H., van Bon, B.W., Kleefstra, T., Yn-
tema, H.G., Kroes, T., Vulto-van Silfhout, A.T., Koolen, D.A.,
de Vries, P., Gilissen, C., et al. (2012). Diagnostic exome
sequencing in persons with severe intellectual disability.
N. Engl. J. Med. 367, 1921–1929.
7. Vulto-van Silfhout, A.T., Hehir-Kwa, J.Y., van Bon, B.W.,
Schuurs-Hoeijmakers, J.H., Meader, S., Hellebrekers, C.J.,
Thoonen, I.J., de Brouwer, A.P., Brunner, H.G., Webber, C.,
et al. (2013). Clinical significance of de novo and inherited
copy-number variation. Hum. Mutat. 34, 1679–1687.
8. Stevens-Kroef, M.J., van den Berg, E., OldeWeghuis, D., Geurts
van Kessel, A., Pfundt, R., Linssen-Wiersma, M., Benjamins,
M., Dijkhuizen, T., Groenen, P.J., and Simons, A. (2014). Iden-
tification of prognostic relevant chromosomal abnormalities
in chronic lymphocytic leukemia using microarray-based
genomic profiling. Mol. Cytogenet. 7, 3.
9. Brett, M., McPherson, J., Zang, Z.J., Lai, A., Tan, E.S., Ng, I.,
Ong, L.C., Cham, B., Tan, P., Rozen, S., and Tan, E.C. (2014).
Massively parallel sequencing of patients with intellectual
disability, congenital anomalies and/or autism spectrumdisor-
ders with a targeted gene panel. PLoS ONE 9, e93409.
10. Wright, C.F., Fitzgerald, T.W., Jones, W.D., Clayton, S., McRae,
J.F., van Kogelenberg, M., King, D.A., Ambridge, K., Barrett,an Journal of Human Genetics 98, 373–381, February 4, 2016 379
D.M., Bayzetinova, T., et al.; DDD study (2015). Genetic diag-
nosis of developmental disorders in the DDD study: a scalable
analysis of genome-wide research data. Lancet 385, 1305–
1314.
11. Wiszniewska, J., Bi, W., Shaw, C., Stankiewicz, P., Kang, S.H.,
Pursley, A.N., Lalani, S., Hixson, P., Gambin, T., Tsai, C.H.,
et al. (2014). Combined array CGH plus SNP genome analyses
in a single assay for optimized clinical testing. Eur. J. Hum.
Genet. 22, 79–87.
12. Lepri, F.R., Scavelli, R., Digilio, M.C., Gnazzo, M., Grotta, S.,
Dentici, M.L., Pisaneschi, E., Sirleto, P., Capolino, R., Baban,
A., et al. (2014). Diagnosis of Noonan syndrome and related
disorders using target next generation sequencing. BMC
Med. Genet. 15, 14.
13. Faesen, A.C., Luna-Vargas, M.P., and Sixma, T.K. (2012). The
role of UBL domains in ubiquitin-specific proteases. Biochem.
Soc. Trans. 40, 539–545.
14. Murtaza, M., Jolly, L.A., Gecz, J., and Wood, S.A. (2015). La
FAM fatale: USP9X in development and disease. Cell. Mol.
Life Sci. 72, 2075–2089.
15. Khut, P.Y., Tucker, B., Lardelli, M., and Wood, S.A. (2007).
Evolutionary and expression analysis of the zebrafish deubi-
quitylating enzyme, usp9. Zebrafish 4, 95–101.
16. Jolly, L.A., Taylor, V., andWood, S.A. (2009). USP9X enhances
the polarity and self-renewal of embryonic stem cell-derived
neural progenitors. Mol. Biol. Cell 20, 2015–2029.
17. Jones, M.H., Furlong, R.A., Burkin, H., Chalmers, I.J.,
Brown, G.M., Khwaja, O., and Affara, N.A. (1996). The
Drosophila developmental gene fat facets has a human ho-
mologue in Xp11.4 which escapes X-inactivation and has
related sequences on Yq11.2. Hum. Mol. Genet. 5, 1695–
1701.
18. Wood, S.A., Pascoe, W.S., Ru, K., Yamada, T., Hirchenhain, J.,
Kemler, R., and Mattick, J.S. (1997). Cloning and expression
analysis of a novel mouse gene with sequence similarity to
the Drosophila fat facets gene. Mech. Dev. 63, 29–38.
19. Fischer-Vize, J.A., Rubin, G.M., and Lehmann, R. (1992). The
fat facets gene is required forDrosophila eye and embryo devel-
opment. Development 116, 985–1000.
20. Dupont, S., Mamidi, A., Cordenonsi, M., Montagner, M., Zac-
chigna, L., Adorno, M., Martello, G., Stinchfield, M.J., Soligo,
S., Morsut, L., et al. (2009). FAM/USP9x, a deubiquitinating
enzyme essential for TGFbeta signaling, controls Smad4
monoubiquitination. Cell 136, 123–135.
21. Friocourt, G., Kappeler, C., Saillour, Y., Fauchereau, F., Rodri-
guez, M.S., Bahi, N., Vinet, M.C., Chafey, P., Poirier, K., Taya,
S., et al. (2005). Doublecortin interacts with the ubiquitin pro-
tease DFFRX, which associates with microtubules in neuronal
processes. Mol. Cell. Neurosci. 28, 153–164.
22. Xie, Y., Avello, M., Schirle, M., McWhinnie, E., Feng, Y., Bric-
Furlong, E., Wilson, C., Nathans, R., Zhang, J., Kirschner,
M.W., et al. (2013). Deubiquitinase FAM/USP9X interacts
with the E3 ubiquitin ligase SMURF1 protein and protects it
from ligase activity-dependent self-degradation. J. Biol.
Chem. 288, 2976–2985.
23. Agrawal, P., Chen, Y.T., Schilling, B., Gibson, B.W., and
Hughes, R.E. (2012). Ubiquitin-specific peptidase 9, X-linked
(USP9X) modulates activity of mammalian target of rapamy-
cin (mTOR). J. Biol. Chem. 287, 21164–21175.
24. Taya, S., Yamamoto, T., Kanai-Azuma,M.,Wood, S.A., and Kai-
buchi, K. (1999). The deubiquitinating enzyme Fam interacts
with and stabilizes beta-catenin. Genes Cells 4, 757–767.380 The American Journal of Human Genetics 98, 373–381, February25. Taya, S., Yamamoto, T., Kano, K., Kawano, Y., Iwamatsu, A.,
Tsuchiya, T., Tanaka, K., Kanai-Azuma, M., Wood, S.A., Mat-
tick, J.S., and Kaibuchi, K. (1998). The Ras target AF-6 is a sub-
strate of the fam deubiquitinating enzyme. J. Cell Biol. 142,
1053–1062.
26. Mouchantaf, R., Azakir, B.A., McPherson, P.S., Millard, S.M.,
Wood, S.A., and Angers, A. (2006). The ubiquitin ligase itch
is auto-ubiquitylated in vivo and in vitro but is protected
from degradation by interacting with the deubiquitylating
enzyme FAM/USP9X. J. Biol. Chem. 281, 38738–38747.
27. Al-Hakim, A.K., Zagorska, A., Chapman, L., Deak, M., Peggie,
M., and Alessi, D.R. (2008). Control of AMPK-related kinases
by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin
chains. Biochem. J. 411, 249–260.
28. Luise, C., Capra, M., Donzelli, M., Mazzarol, G., Jodice, M.G.,
Nuciforo, P., Viale, G., Di Fiore, P.P., and Confalonieri, S.
(2011). An atlas of altered expression of deubiquitinating
enzymes in human cancer. PLoS ONE 6, e15891.
29. Schwickart,M.,Huang,X., Lill, J.R., Liu, J., Ferrando, R., French,
D.M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson,
J., et al. (2010).DeubiquitinaseUSP9X stabilizesMCL1 andpro-
motes tumour cell survival. Nature 463, 103–107.
30. Firth, H.V., Hurst, J.A., and Hall, J.G. (2009). Clinical Genetics
(New York: Oxford University Press).
31. Deng, X., Berletch, J.B., Nguyen, D.K., and Disteche, C.M.
(2014). X chromosome regulation: diverse patterns in devel-
opment, tissues and disease. Nat. Rev. Genet. 15, 367–378.
32. Cotton, A.M., Price, E.M., Jones, M.J., Balaton, B.P., Kobor,
M.S., and Brown, C.J. (2015). Landscape of DNA methylation
on the X chromosome reflects CpG density, functional
chromatin state and X-chromosome inactivation. Hum.
Mol. Genet. 24, 1528–1539.
33. Berletch, J.B., Yang, F., Xu, J., Carrel, L., and Disteche, C.M.
(2011). Genes that escape from X inactivation. Hum. Genet.
130, 237–245.
34. Yang, C., Chapman, A.G., Kelsey, A.D., Minks, J., Cotton,
A.M., and Brown, C.J. (2011). X-chromosome inactivation:
molecular mechanisms from the human perspective. Hum.
Genet. 130, 175–185.
35. Morleo, M., and Franco, B. (2008). Dosage compensation of
the mammalian X chromosome influences the phenotypic
variability of X-linked dominant male-lethal disorders.
J. Med. Genet. 45, 401–408.
36. Carrel, L., and Willard, H.F. (2005). X-inactivation profile
reveals extensive variability in X-linked gene expression
in females. Nature 434, 400–404.
37. Talebizadeh, Z., Simon, S.D., and Butler, M.G. (2006). X chro-
mosome gene expression in human tissues: male and female
comparisons. Genomics 88, 675–681.
38. Zweier, C., Kraus, C., Brueton, L., Cole, T., Degenhardt, F., En-
gels, H., Gillessen-Kaesbach, G., Graul-Neumann, L., Horn,
D., Hoyer, J., et al. (2013). A new face of Borjeson-For-
ssman-Lehmann syndrome? De novo mutations in PHF6 in
seven females with a distinct phenotype. J. Med. Genet. 50,
838–847.
39. Peeters, S.B., Cotton, A.M., and Brown, C.J. (2014). Variable
escape from X-chromosome inactivation: identifying factors
that tip the scales towards expression. BioEssays 36, 746–756.
40. Snijders Blok, L., Madsen, E., Juusola, J., Gilissen, C., Baralle,
D., Reijnders, M.R., Venselaar, H., Helsmoortel, C., Cho,
M.T., Hoischen, A., et al.; DDD Study (2015). Mutations in
DDX3X are a common cause of unexplained intellectual4, 2016
disability with gender-specific effects onWnt signaling. Am. J.
Hum. Genet. 97, 343–352.
41. Xu, J., Taya, S., Kaibuchi, K., and Arnold, A.P. (2005). Sexually
dimorphic expression of Usp9x is related to sex chromosome
complement in adult mouse brain. Eur. J. Neurosci. 21, 3017–
3022.
42. Homan, C.C., Kumar, R., Nguyen, L.S., Haan, E., Raymond,
F.L., Abidi, F., Raynaud, M., Schwartz, C.E., Wood, S.A.,
Gecz, J., and Jolly, L.A. (2014). Mutations in USP9X are associ-
ated with X-linked intellectual disability and disrupt neuronal
cell migration and growth. Am. J. Hum. Genet. 94, 470–478.
43. Paemka, L., Mahajan, V.B., Ehaideb, S.N., Skeie, J.M., Tan,
M.C., Wu, S., Cox, A.J., Sowers, L.P., Gecz, J., Jolly, L., et al.
(2015). Seizures are regulated by ubiquitin-specific peptidase
9 X-linked (USP9X), a de-ubiquitinase. PLoS Genet. 11,
e1005022.
44. Iossifov, I., O’Roak, B.J., Sanders, S.J., Ronemus, M., Krumm,
N., Levy, D., Stessman, H.A., Witherspoon, K.T., Vives, L., Pat-
terson, K.E., et al. (2014). The contribution of de novo coding
mutations to autism spectrum disorder. Nature 515, 216–221.
45. Nagy, E., and Maquat, L.E. (1998). A rule for termination-
codon position within intron-containing genes: whenThe Americnonsense affects RNA abundance. Trends Biochem. Sci. 23,
198–199.
46. Lewis, B.P., Green, R.E., and Brenner, S.E. (2003). Evidence for
the widespread coupling of alternative splicing and nonsense-
mediated mRNA decay in humans. Proc. Natl. Acad. Sci. USA
100, 189–192.
47. Stegeman, S., Jolly, L.A., Premarathne, S., Gecz, J., Richards,
L.J., Mackay-Sim, A., andWood, S.A. (2013). Loss of Usp9x dis-
rupts cortical architecture, hippocampal development and
TGFb-mediated axonogenesis. PLoS ONE 8, e68287.
48. Ware, S.M., Aygun, M.G., and Hildebrandt, F. (2011). Spec-
trum of clinical diseases caused by disorders of primary cilia.
Proc. Am. Thorac. Soc. 8, 444–450.
49. Tucker, R.W., Pardee, A.B., and Fujiwara, K. (1979). Centriole
ciliation is related to quiescence and DNA synthesis in 3T3
cells. Cell 17, 527–535.
50. Vorobjev, I.A., and Chentsov YuS. (1982). Centrioles in the
cell cycle. I. Epithelial cells. J. Cell Biol. 93, 938–949.
51. Murray, R.Z., Jolly, L.A., andWood, S.A. (2004). The FAM deu-
biquitylating enzyme localizes to multiple points of protein
trafficking in epithelia, where it associates with E-cadherin
and beta-catenin. Mol. Biol. Cell 15, 1591–1599.an Journal of Human Genetics 98, 373–381, February 4, 2016 381
